0 0 0 0 0 -0.0703125000000001 -0.0703125000000001 -0.0889062499999999
Sign Up Today X
Thanks for submitting the form.
Stockreport

InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones

InflaRx N.V. (IFRX)  More Company Research Source: GlobeNewswire
Last inflarx n.v. earnings: 8/14 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: inflarx.com/home/investors/press-releases/01-2018--inflarx-to-present-at-upcoming-investor-conferences.html
Received European Commission approval for GOHIBIC® (vilobelimab) for the treatment of SARS-CoV-2-induced acute respiratory distress syndrome (ARDS)Achieved 30-patient recruitment milestone in Phase 3 vilobelimab trial in pyoderma gangrenosum (PG) to enable an expected interim analysis for trial size adaptation or futility by the end of May 2025Dosed first patient in Phase 2a trial for oral C5aR inhibitor, INF904, with topline data in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) expected in summer 2025Multiple data presentations at AAD 2025 highlighting the potential of vilobelimab in reducing systemic inflammationCash, cash equivalents and marketable securities of €55.2 million as of December 31, 2024Additional €28.7 million ($30.0 million) in gross proceeds subsequently raised by an underwritten public offering of ordinary shares and pre-funded warrants on February 18, 2025InflaRx’s cash runway significantly extended, with sufficient cash, cash equivalents an [Read more]
IMPACT SNAPSHOT EVENT TIME: IFRX
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
IFRX alerts
from News Quantified
IFRX
NEWS
IFRX
Earnings
IFRX
Analyst Actions
IFRX
SEC Filings
Stockreport

InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones

InflaRx N.V.  (IFRX) 
More Company Research Source: GlobeNewswire
Last inflarx n.v. earnings: 8/14 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: inflarx.com/home/investors/press-releases/01-2018--inflarx-to-present-at-upcoming-investor-conferences.html
Received European Commission approval for GOHIBIC® (vilobelimab) for the treatment of SARS-CoV-2-induced acute respiratory distress syndrome (ARDS)Achieved 30-patient recruitment milestone in Phase 3 vilobelimab trial in pyoderma gangrenosum (PG) to enable an expected interim analysis for trial size adaptation or futility by the end of May 2025Dosed first patient in Phase 2a trial for oral C5aR inhibitor, INF904, with topline data in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) expected in summer 2025Multiple data presentations at AAD 2025 highlighting the potential of vilobelimab in reducing systemic inflammationCash, cash equivalents and marketable securities of €55.2 million as of December 31, 2024Additional €28.7 million ($30.0 million) in gross proceeds subsequently raised by an underwritten public offering of ordinary shares and pre-funded warrants on February 18, 2025InflaRx’s cash runway significantly extended, with sufficient cash, cash equivalents an [Read more]
IMPACT SNAPSHOT
EVENT TIME:
IFRX
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS